ReviewNature reviews. Clinical oncology2011
Metastasis-suppressor genes in clinical practice: lost in translation?
Review in Nature reviews. Clinical oncology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed.
- RCAN1.4 regulates tumor cell engraftment and invasion in a thyroid cancer to lung metastasis-on-a-chip microphysiological system.Biofabrication · 2024Article
- Metastasis suppressor genes in clinical practice: are they druggable?Cancer metastasis reviews · 2023Review
- Long-chain fatty acyl coenzyme A inhibits NME1/2 and regulates cancer metastasis.Proceedings of the National Academy of Sciences of the United States of America · 2022Article
- The peptide mimicking small extracellular ring domain of CD82 inhibits tumor cell migration in vitro and metastasis in vivo.Journal of cancer research and clinical oncology · 2021Article
- Small Ones to Fight a Big Problem-Intervention of Cancer Metastasis by Small Molecules.Cancers · 2020Review
- The NDPK/NME superfamily: state of the art.Laboratory investigation; a journal of technical methods and pathology · 2018Article
- BRMS1 Expression in Surgically Resected Lung Adenocarcinoma Predicts Future Metastases and Is Associated with a Poor Prognosis.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2018Article
- Genomic signatures for paclitaxel and gemcitabine resistance in breast cancer derived by machine learning.Molecular oncology · 2016Article
- Single-cell Migration Chip for Chemotaxis-based Microfluidic Selection of Heterogeneous Cell Populations.Scientific reports · 2015Article
- RECK controls breast cancer metastasis by modulating a convergent, STAT3-dependent neoangiogenic switch.Oncogene · 2015Article
- Article
- Dysregulated miR-645 affects the proliferation and invasion of head and neck cancer cell.Cancer cell international · 2015Article
- Drug Development for Metastasis Prevention.Critical reviews in oncogenesis · 2015Review
- Toward a drug development path that targets metastatic progression in osteosarcoma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2014Article
- Loss of CADM1 expression is associated with poor prognosis and brain metastasis in breast cancer patients.Oncotarget · 2014Article
- miR181b is induced by the chemopreventive polyphenol curcumin and inhibits breast cancer metastasis via down-regulation of the inflammatory cytokines CXCL1 and -2.Molecular oncology · 2014Article
- The metastasis suppressor, N-myc downstream-regulated gene 1 (NDRG1), inhibits stress-induced autophagy in cancer cells.The Journal of biological chemistry · 2014Article
- Engineered reversal of drug resistance in cancer cells--metastases suppressor factors as change agents.Nucleic acids research · 2014Article
- Lung cancer with gastrointestinal metastasis - review of theories of metastasis with three rare case descriptions.Cancer microenvironment : official journal of the International Cancer Microenvironment Society · 2013Article
- Evolution and dynamics of pancreatic cancer progression.Oncogene · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Over the past 25 years, an expanding set of metastasis-suppressor genes (MSGs) has been identified that specifically regulate metastasis formation without affecting primary growth. MSGs are involved in diverse molecular processes in multiple tumor types. Given the wealth of metastasis biology that underlies their functions, treatment strategies based on MSGs have an unparalleled potential to improve patient care. Using NM23 as a prime example, we discuss how specific MSGs have been used as prognostic markers, tools for predicting response to treatment, and targets for the development of novel therapies. Barriers specific to the translation of MSG biology into clinical practice are reviewed and future research directions necessary for clinical advances are delineated. Although to date the impact of MSGs on patient care is limited, it is an expanding field with vast potential to help develop new treatments and identify patients who will most benefit from them.
Indexed as
Identifiers
21522123What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.